Background-Intensity modulated radiotherapy for stage III lung cancer has become commonplace in the United States in the absence of randomized controlled trials. We used a large, population-based database to determine which factors led to increased utilization of IMRT and to evaluate associations of IMRT with toxicities.
Introduction
The incidence of stage III non-small cell lung cancer (NSCLC) is likely to rise considerably in the coming decade due to demographic trends [1] . The majority of these patients will require radiation for definitive therapy or as an adjuvant to surgical management [2] [3] [4] . In contemporary practice, radiotherapy is mostly delivered with one of two technologies: 3D conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT). In 3DCRT, axial imaging is used to target a tumor with several radiation fields, whose sizes, shapes, and angles of entry are selected by a radiation oncologist. With IMRT, the radiation oncologist instead delineates a volume containing the tumor. This volume is then targeted by many small beamlets whose contributions are determined by computer algorithm. Given the disparity in how each technique is implemented, it cannot be taken for granted that the two technologies will yield equivalent outcomes.
There are no prospective trials comparing the two techniques for any thoracic malignancy. In the absence of phase III data, one hopes that sound clinical rationale accounts for the choice of radiotherapy, but other factors may play a role. These factors include perceived dosimetric advantages [5, 6] , accessibility of technology [7] , financial considerations [8, 9] , a desire to escalate dose [10] , or a need to meet normal organ dose constraints [11] [12] [13] [14] . Determining which of these issues influences everyday practice is important as the selection of radiation technique can have far-reaching consequences for patients and the health care system.
Population-based data can generate hypotheses regarding the factors that promote or slow the adoption of advanced technologies. Furthermore, this data can be used to evaluate the clinical impact of those technologies after their introduction. To that end, we performed a population-based analysis using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to identify predictors of IMRT use and associations of IMRT use with radiation-related toxicities among patients with stage III NSCLC diagnosed from [2001] [2002] [2003] [2004] [2005] [2006] [2007] . Specifically, we sought to determine the extent to which clinical versus non-clinical factors influenced adoption of IMRT and to compare acute pulmonary and esophageal toxicities associated with IMRT versus 3DCRT.
Methods

Data Source and Study Sample
The Surveillance, Epidemiology, and End Results (SEER)-Medicare database captures claims data for cancers diagnosed in Medicare beneficiaries who reside within 16 geographic catchment areas representing 26% of the US population. The case ascertainment rate for the SEER data is approximately 98% [15] . In this study, demographic and tumor characteristics for incident malignancies diagnosed from Table 1 ). Patients were excluded from this study if they did not have complete Medicare Part A and B records from 12 months prior to diagnosis to 6 months after diagnosis (or until death); or if they had health maintenance organization (HMO) coverage within the same timeframe (Supplementary Table 1 ). Patients with any second cancer diagnosed within 6 months of the index lung cancer were also excluded as billing records could not discriminate between procedures performed for the index cancer versus the second cancer.
Because our goal was to compare patients treated with 3DCRT and IMRT, patients treated with other radiation modalities (proton therapy, brachytherapy, and 2-D radiotherapy) were excluded from the analysis. Finally, to ensure that radiotherapy was not directed at metastatic targets, we excluded patients with diagnosis codes for brain metastasis, adrenal, bone or liver metastases submitted in the period two weeks before the date of diagnosis until the start of radiotherapy. These criteria yielded a final sample of 3,986 patients (Supplementary Table 1 ).
Treatment Strategies
Medicare claims using International Classification of Diseases, 9th Revision (ICD-9) and Clinical Modification and Current Procedural Terminology/Healthcare Common Procedure Coding System (CPT) codes were utilized to extract claims for diagnostic procedures, treatments, and toxicity outcomes. Therapies occurring within 6 months of diagnosis were considered to be part of the initial treatment strategy (Supplementary Table 2 ). We classified patients as having received IMRT if a claims code confirming actual delivery of intensitymodulated treatment (77418, 0073T, G0174) was present. Three-dimensional conformal radiation was defined by the presence of both a claim for "three dimensional reconstruction of the tumor volume" (77295) and non-IMRT external beam radiation delivery (77402-77416) [16] . The number of radiotherapy fractions was calculated by counting the number of unique CPT codes for radiation delivery using a time window from the start of radiation delivery until 3 months thereafter. Based on treatment claims, the overall treatment strategy was stratified into four categories: trimodality therapy, chemotherapy and radiation, surgery and radiation, and radiation alone.
Other Covariates
Patient demographic variables from the SEER data included age at diagnosis, race, and gender. Baseline patient characteristics were determined using Medicare claims from an interval of 12 months before to 1 month after diagnosis [17] . The Charlson comorbidity index with Klabunde modification was determined from ICD-9 codes using published methods [18] [19] [20] . Chronic obstructive pulmonary disease (COPD) (491.2x, 493.2, 496) was not included in the index and was reported separately. Patients were classified as oxygen users if durable medical equipment claims included oxygen equipment. Using the method of Davidoff et al., a performance status covariate was generated using claims for medical assistance services or devices (canes, walkers, home hospital beds, or home health care) [21] .
Tumor characteristics extracted from the SEER data included AJCC version 6 stage (IIIA, IIIB), laterality, and lung subsite [22] . Tumor size classifications are based upon maximum length of the tumor in centimeters and stratifications were applied using AJCC version 7 Tstage thresholds; invasion of local structures is not reflected in the tumor size classifications. To adjust for stage migration, the use of mediastinal sampling and positron emission tomography (PET) within a time period extending from 2 weeks prior to diagnosis to the start of radiotherapy were assessed (Supplementary Table 2 ).
Practice environment characteristics reflective of the patient's county of residence were evaluated. Year of diagnosis, geographic region, and whether the setting was urban or rural were obtained from the SEER data. County-level density of radiation oncologists was determined using the Area Resource File for 2001-2005 in accordance with published methods [8] . The type of treatment center was determined from claims for radiation delivery, also in accordance with published methods [8, 23, 24] .
Toxicity Outcomes
Toxicities were determined from Medicare claims (Supplementary Table 3 ). We evaluated the incidence of lung toxicity using two definitions. A narrow definition only included the ICD-9 diagnosis code for "unspecified acute pulmonary toxicity due to radiation". The broad definition also included claims codes for nonspecific lung infiltrates (ie, not attributed to volume overload and no infectious organism identified). Acute esophagus toxicity was defined using diagnosis codes for esophagitis, dehydration, feeding tube placement, and mucositis. These components were analyzed individually and in aggregate.
In accordance with the natural history of radiation toxicities, toxicities were scored if the relevant claims code was submitted within 8 months after the start of radiotherapy in order to capture 2 months of radiation therapy and 6 months of followup. Sensitivity analyses were performed wherein the 8-month cutoff was shortened to 4 months and extended to 14 months. Due to a low number of toxic events, chronic toxicities were not able to be robustly studied using this data set.
Statistical Analysis
Predictors for IMRT use were determined using logistic regression. Bivariate associations at a significance level of 0.20 or less were included in an initial multivariable logistic regression model. The model was modified using backwards elimination of all predictor variables whose removal did not diminish the fit of the model (P > 0.05). Initially excluded covariates were then re-assessed using forwards elimination to generate a final model. Goodness-of-fit was assessed using the Hosmer-Lemeshow test.
In the second part of our analysis, the association of radiotherapy technique with acute toxicities was assessed. The cumulative incidence of adverse events was determined using the Kaplan-Meier method with censorship at the earliest of the following: loss of Medicare coverage, conversion to HMO coverage, death, or the end of the study period. For each endpoint, the proportional hazards assumption with respect to radiation technique was tested visually by inspection of log-log plots and analytically using Schoenfield residuals. The relationship between radiation technique and toxicity was determined with multivariate regression adjusted for factors that were considered statistically significant at P<0.20 in univariate analyses. Clinically important covariates including age, oxygen status, performance status, stage, number of radiation treatments, and treatment strategy were included in the final model regardless of their unadjusted P values. The model was stratified by SEER region and the year of diagnosis to account for variations with geography and time. Prespecified interaction terms were used to determine whether the effect of radiation technique differed with respect to the clinically important covariates listed above. The Gronnesby and Morgan test was used to assess goodness-of-fit for final models.
Propensity-score matching was also performed to validate the findings of the multivariate regression. Propensity scores were generated using a logistic model with radiation technique as the dependent variable. The independent variables included all other available covariates. Patients were matched 1:1 using nearest neighbor technique with caliper distance limited to 25% of the standard deviation of the pooled propensity scores. Standardized difference was used to assess covariate balance between cohorts with a threshold of 0.20 [25] . Proportional hazards models, stratified by matched pair [26] and adjusted for unbalanced covariates, were generated to compare the cohorts. Because combined chemotherapy and radiation is the dominant strategy for stage III NSCLC patients, we performed a sensitivity analysis wherein propensity-score matching was limited to patients treated with this strategy.
All statistical analyses were 2-sided with P ≤ 0.05 and conducted using STATA v.10 (College Station, TX). Our institutional review board granted this study exempt status.
Results
Predictors of IMRT Use
Among the 3,986 patients, median age was 75 years, 54.1% were male, and 62% had IIIA disease (Table 1) . IMRT use rose from 0.5% in 2001 to 14.7% in 2007 (Figure 1 ) (P<0.0001). Multivariate logistic regression identified three predictors for IMRT use (Goodness-of-fit P=0.39). As expected, IMRT use rose with the year of diagnosis. IMRT use was also associated with certain SEER geographic regions. The New Jersey registry was selected as the referent group because it contained the most patients and because the proportion receiving IMRT in this registry (6.8%) approximated the proportion in the entire cohort (6.5%). Compared to New Jersey, IMRT was used less often in Connecticut, Iowa, Georgia, and Kentucky and more often in New Mexico and Los Angeles ( Table 2) . Treatment in a freestanding center was strongly associated with IMRT use (odds ratio, 2.10; 95% confidence interval [CI], 1.59-2.77, P<0.001). After multivariate adjustment, patient, tumor, diagnostic, and treatment covariates were not significant predictors of IMRT use.
Proportional Hazards Analysis of Acute Toxicities
The overall incidence of acute lung toxicity within 8 months of starting radiotherapy was 10.5% in the IMRT group and 7.8% in the 3DCRT group (P=0.12) using the narrow definition, and 38.9% (IMRT) and 37.5% (3DCRT) (P=0.80) using the broad definition. In multivariate analysis, IMRT was not associated with acute pulmonary toxicity, regardless of whether the narrow (Hazard ratio [HR], 1.31; 95%CI, P=0.22) or broad (HR, 1.00; 95%CI 0.81-1.24, P=0.98) definition was used (Table 3, Figure 2 ). Higher comorbidity score and male sex were associated with acute lung toxicity (Supplementary Tables 4-5 ).
The overall incidence of acute esophagus toxicity within 8 months of starting radiotherapy was 44% (IMRT) and 42% (3DCRT) (P=0.58). In multivariate analysis, IMRT was not associated with the cumulative endpoint of acute esophagus toxicity (HR, 1.06; 95%CI 0.87-1.30; P=0.56) (Table 3, Figure 2 ). IMRT was also not associated with any of the individual components of the cumulative endpoint (Table 3, Supplementary Tables 7-10) . Predictors for the cumulative endpoint of esophageal toxicity included advanced age, higher comorbidity score, absence of PET staging, combining chemotherapy with radiation, and the number of radiotherapy fractions (Supplementary Table 6 ).
For all toxicity endpoints, the proportional hazards assumption with respect to radiation technique was satisfied, and goodness-of-fit for all final models was acceptable (P>0.05). Significant interactions between radiation technique and clinically relevant covariates were not observed in any model. Finally, all findings were unchanged if the window for acute events was shortened to 4 months or extended to 14 months.
Propensity-Score Matching Analysis of Acute Toxicities
Two hundred fifty six (99%) of the IMRT patients were successfully matched to 3DCRT control patients. The paired cohorts were well-balanced across all covariables (Supplementary Table 11 ). IMRT was not associated with lung toxicity using the narrow (HR, 1.64; 95%CI 0.84-3.19, P=0.14) or broad definitions (HR 0.96, 95%CI, 0.70-1.43, P=0.81) (Table 3, Figure 2 ). Likewise IMRT was not associated with acute esophagus toxicity using the comprehensive definition (HR, 1.21; 95%CI 0.88-1.64, P=0.24) or using the component endpoints (Table 3) . These results were unchanged if the window for scoring acute events was shortened to 4 months or extended to 14 months. Propensity-score matching analysis limited to patients treated with chemotherapy and radiation yielded similar results as the entire population (Supplementary Table 12 ).
Discussion
Proponents of highly conformal radiotherapy, such as IMRT, for treating lung cancer have argued that these technologies can minimize normal tissue toxicity, which in turn can improve patient compliance and allow dose escalation [27] [28] [29] . However, concern has been raised that the use of advanced technologies such as IMRT can also be influenced by nonclinical factors [30] [31] [32] [33] . Therefore, our first objective in this study was to determine whether clinical issues -such as tumor size classification, IIIB stage, or high comorbidity scoredrove the increased utilization of IMRT between 2001 and 2007. Using a database of nearly 4,000 stage III lung cancer patients treated in everyday practice, we found that clinical factors did not predict for IMRT use. Aside from the year of diagnosis, the only factors that were significant predictors of IMRT use were treatment within certain geographic regions and treatment within a freestanding radiation center.
Freestanding radiotherapy centers rose in prominence beginning in the late 1980s and were supported by a higher Medicare fee schedule to compensate their higher costs of operation [34] . The purpose of these centers was to improve access to medically underserved area, but whether this has been achieved is controversial [9, 34] . In our analysis, we found that treatment at these centers was associated with twice the odds of receiving IMRT for lung cancer. One explanation is that these centers may have had greater willingness and flexibility to pursue capital equipment purchases and introduce new technology. Another factor may have been differences in reimbursement. During the study period, Medicare reimbursement at freestanding centers for IMRT was approximately twice that received by hospital-based centers [8] .
Additional research is required to determine whether either of these mechanisms (or some other factor) is responsible for the increased utilization of IMRT at freestanding centers. To our knowledge, this is the first study to identify this phenomenon for lung cancer radiotherapy, but it has been observed in breast and prostate cancer practice and even in the setting of palliative care [8, 23, 24, 31, 35] . Identification of the factors that account for this effect may help to craft policies that optimize high value radiation treatment. This avenue of health services research is especially timely because the introduction of accountable care organizations in the United States will provide a framework for initiatives that foster responsible utilization of new technologies [31, [36] [37] [38] .
In the second portion of our study, we compared the incidences of acute toxicities following IMRT and 3DCRT. Using two different analytic techniques, we found no difference in toxicity incidence between patients treated with 3DCRT and IMRT. Because our study period captured the earliest users of IMRT, it was reassuring to find similar rates of acute toxicity when comparing this new technology to a mature standard-of-care. For acute lung injury, our findings were consistent with prior single-institution reports which also did not find worse rates of pneumonitis despite the theoretical risks associated with increased lowdose lung exposure from intensity-modulated beams [13, 14] . These other reports actually found a lower burden of acute pneumonitis with IMRT, but it is not unexpected that outcomes in a single institution with strict quality assurance protocols would be different than those found in a diverse, population-based cohort.
With regard to esophagus toxicity, IMRT dose-painting is often used to spare the esophagus from high-dose regions, but we did not observe a clinical correlate for this practice. Again, it is possible that the early adoption phase of IMRT was not yet advanced enough to make a measurable impact on this endpoint. Another possibility, suggested by the first portion of our investigation, is that patients at high risk for esophagitis, such as those with IIIB disease, were not necessarily selected for IMRT, reducing the likelihood of detecting a benefit.
An important strength of this analysis was the implementation of new methodologies to address limitations inherent to population-based databases [21] . Though population-based analyses have emerged as powerful tools for studying radiotherapy in lung cancer [16, [39] [40] [41] [42] [43] , a weakness is the absence of data for certain prognostic factors. For instance, the SEERMedicare database lacks data for pulmonary function and ECOG performance status. To overcome this limitation, we generated proxy covariates including COPD status, supplemental oxygen use, and claims for medical assistance to approximate the "classic" prognostic factors. Additionally, incorporating the number of radiotherapy fractions provided some measure of adjustment for dose-escalation. We infer that adding these additional covariates to the rich set of data available in SEER-Medicare reduced the impact of hidden selection bias.
This study has several limitations. First, IMRT technique has been considerably refined since 2007 and contemporary outcomes, including acute toxicities, may be improved now when compared to the findings from our cohort. Second, our analysis is observational and may harbor bias despite adjustment for measurable confounders. Third, the use of diagnosis claims codes did not provide insight into the subjective intensity of the toxicity. Therefore, if the benefit of IMRT is to reduce the grade of toxicities rather than their incidence, our methodology may not have detected this advantage. Finally, chronic toxicities and survival were not addressed in this analysis. The combination of a relatively low number of patients in the IMRT cohort and low frequency of events prevented rigorous statistical analysis of these endpoints. Future studies with updated SEER-Medicare data will address this deficit.
Conclusion
Increased utilization of IMRT for NSCLC between 2001 and 2007 was associated with practice factors rather than clinical variables. Early use of IMRT resulted in similar rates of pulmonary and esophagus toxicity as 3DCRT. These findings will hopefully encourage confirmatory prospective trials that quantify the comparative efficacy, and morbidity of the two techniques.
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